Titan Spine closed a round of Series B financing for an undisclosed amount with its investor Southlake Equity Group. Proceeds of the round will support product additions, sales team expansion and accelerated R&D.
This is our first mention of Titan Spine this year. Last November, the company entered the Australian market and announced first surgeries in the region with Endoskeleton® interbody fusion devices and surface technology. Endoskeleton implants feature Titan Spine’s proprietary nanoLOCK® surface technology.
nanoLOCK—the only nanotechnology cleared by the FDA for orthopaedic applications—was launched in October 2016, following FDA 510(k) clearance in late 2014, and features a micro- and nano-scaled architecture designed to improve the osteogenic response and support fusion.
Titan Spine closed a round of Series B financing for an undisclosed amount with its investor Southlake Equity Group. Proceeds of the round will support product additions, sales team expansion and accelerated R&D.
This is our first mention of Titan Spine this year. Last November, the company entered the Australian market and announced first...
Titan Spine closed a round of Series B financing for an undisclosed amount with its investor Southlake Equity Group. Proceeds of the round will support product additions, sales team expansion and accelerated R&D.
This is our first mention of Titan Spine this year. Last November, the company entered the Australian market and announced first surgeries in the region with Endoskeleton® interbody fusion devices and surface technology. Endoskeleton implants feature Titan Spine’s proprietary nanoLOCK® surface technology.
nanoLOCK—the only nanotechnology cleared by the FDA for orthopaedic applications—was launched in October 2016, following FDA 510(k) clearance in late 2014, and features a micro- and nano-scaled architecture designed to improve the osteogenic response and support fusion.
Copy to clipboard 
